AngioDynamics (NASDAQ:ANGO) Releases FY25 Earnings Guidance

AngioDynamics (NASDAQ:ANGO) updated its FY25 earnings guidance on Wednesday. The company provided EPS guidance of ($0.38)-($0.34) for the period, compared to the consensus EPS estimate of ($0.40). The company issued revenue guidance of $282-288 million, compared to the consensus revenue estimate of $283.86 million. AngioDynamics also updated its FY 2025 guidance to -0.380–0.340 EPS.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on ANGO shares. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a report on Tuesday, December 10th. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating for the company in a report on Friday, October 4th.

AngioDynamics Stock Performance

Shares of ANGO opened at $12.94 on Thursday. The firm has a market capitalization of $525.80 million, a PE ratio of -2.12 and a beta of 0.59. The stock has a 50 day simple moving average of $7.99 and a 200 day simple moving average of $7.34. AngioDynamics has a 52-week low of $5.26 and a 52-week high of $13.13.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Wednesday, January 8th. The medical instruments supplier reported ($0.04) EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million for the quarter, compared to analyst estimates of $70.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. The firm’s quarterly revenue was down .1% on a year-over-year basis. During the same period last year, the business posted ($0.05) earnings per share. Equities research analysts predict that AngioDynamics will post -0.41 EPS for the current fiscal year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.